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ABSTRACT
CKD prevalence estimation is central to CKD management and prevention planning at the population
level. This study estimated CKD prevalence in the European adult general population and investigated
international variation in CKD prevalence by age, sex, and presence of diabetes, hypertension, and
obesity. We collected data from 19 general-population studies from 13 European countries. CKD stages
1–5 was deﬁned as eGFR,60 ml/min per 1.73 m2, as calculated by the CKD-Epidemiology Collaboration
equation, or albuminuria .30 mg/g, and CKD stages 3–5 was deﬁned as eGFR,60 ml/min per 1.73 m2.
CKD prevalence was age- and sex-standardized to the population of the 27 Member States of the Euro-
pean Union (EU27). We found considerable differences in both CKD stages 1–5 and CKD stages 3–5
prevalence across European study populations. The adjusted CKD stages 1–5 prevalence varied between
3.31% (95%conﬁdence interval [95%CI], 3.30% to3.33%) inNorway and 17.3% (95%CI, 16.5% to 18.1%) in
northeast Germany. The adjustedCKD stages 3–5 prevalence varied between 1.0% (95%CI, 0.7% to 1.3%)
in central Italy and 5.9% (95% CI, 5.2% to 6.6%) in northeast Germany. The variation in CKD prevalence
stratiﬁed by diabetes, hypertension, and obesity status followed the same pattern as the overall preva-
lence. In conclusion, this large-scale attempt to carefully characterize CKDprevalence in Europe identiﬁed
substantial variation in CKD prevalence that appears to be due to factors other than the prevalence of
diabetes, hypertension, and obesity.
J Am Soc Nephrol 27: 2135–2147, 2016. doi: 10.1681/ASN.2015050542
CKD reduces lifespan signiﬁcantly.1 Individuals
with CKD have an increased risk of cardiovascular
disease and may develop ESRD.1,2 Fortunately, the
development of these complications can be delayed
or prevented.1
CKD prevalence estimation is central to CKD
management and prevention planning at the pop-
ulation level.3 Identiﬁcation of countries with a rel-
atively low or high CKD prevalence will guide the
medical community and policy makers where to
focus prevention and disease management strate-
gies. To date, international comparisons have been
hampered by differences in national age and sex
distributions and in deﬁnitions of CKD.4Moreover,
prevalence estimates are inﬂuenced by the use of
different creatinine determination methods.5,6
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Because diabetes, hypertension, and obesity are important risk
factors for CKD,2 the prevalence of these diseases should be
taken into account when comparing CKD prevalence.
Whether disparities in CKD prevalence are explained by these
risk factors will guide policy makers to focus on secondary or
primary prevention.
Therefore the purpose of our study was (1) to estimate the
CKD prevalence in the adult general population across Europe,
and (2) to investigate variation in prevalence across countries
by age, sex, and the presence of diabetes, hypertension, and
obesity. We collected data from 19 general population-based
studies from 13 European countries and estimated CKD prev-




We included data from 19 general population-based studies
from 13 European countries (Table 1). Table 2 presents study
population characteristics and laboratory methods for the
nine studies using isotope dilution mass spectrometry
(IDMS) traceable creatinine, which included a large spectrum
of the adult population ($45 years). Supplemental Appendix
1, Table 1 presents these data for all 19 studies for subjects aged
$65 years.
Representativeness of Study Populations
Thirteen (68%) studies used a population register/electoral
rolls as sampling frame to identify eligible participants (Table
1). Four (21%) studies used general practitioner lists and two
studies used other sampling frames. The response varied be-
tween 20% and 84%, with two studies not providing a re-
sponse percentage. The response was at least 60% in ten
(59%) studies. Five studies independently performed nonre-
sponse analyses to test representativeness of study popula-
tions.7–11 Two studies (Survey of Lifestyle and Attitudes &
Nutrition in Ireland, and Prevalence of Diabetes and Risk Fac-
tors in Portugal) weighted the study population to correct for
oversampling of females and older individuals in comparison
to their respective national population. In the nine studies that
covered the entire adult population, the age and sex distribu-
tion was not signiﬁcantly different from the age and sex dis-
tribution of their respective target populations (Table 1).
Creatinine Measurements
Serumcreatininewasdeterminedby Jaffe assays in themajority
of studies (n=14; 74%) and four studies used enzymatic assays
(21%). The Medical Research Council trial of assessment and
management of older people in the community study used both
Jaffe and enzymatic assays, with the majority of laboratories
using Jaffe assays. IDMS standardization was used in 13 studies
(68%), of which the CKD prevalence estimates are presented
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studies using non–IDMS-standardized creatinine (n=6, 32%)
are presented exclusively in Supplemental Appendix 1.
Albuminuria Measurements
Of the 11 studies that collected albuminuria data, ten (91%)
used immunoassays to measure urinary albumin. Two studies
(18%) used dipsticks to assess albuminuria presence, which
was conﬁrmed by immunoassay in the Initiative on Nephrop-
athy, of relevance to public health,which isChronic, possibly in
its Initial stages, and carries a Potential risk of major clinical
Endpoints study.
CKD Stage 1–5 Prevalence
Adult Population
Prevalence estimates were adjusted to the age and sex distri-
bution of the population of the 27 Member States of the
European Union (EU27) in 200512 to correct for differences in
national age and sex distributions. The adjusted CKD stages
1–5 prevalence in the adult population, including subjects
aged 20–74 years, for studies using IDMS-standardized creat-
inine varied between 3.31% (95% conﬁdence interval [95%
CI], 3.30 to 3.33) in Norway and 17.3% (95% CI, 16.5 to 18.1)
in the Northeast German Study of Health in Pomeranzia
(SHIP) study (Supplemental Appendix 1, Figure 1).
Supplemental Appendix 1, Table 2 shows the unadjusted
and adjusted CKD stages 1–5 prevalence in the adult popula-
tion, for both IDMS and non-IDMS studies. For studies using
non–IDMS-standardized creatinine, the unadjusted and ad-
justed CKD stages 1–5 prevalence in the adult population is
graphically presented in Supplemental Appendix Figure 1.
Across Age Strata
Figure 1 shows the geographic variation in the adjusted CKD
stages 1–5 prevalence in the population aged 45–74 years, for
studies using IDMS-standardized creatinine. Figure 2A shows
this adjusted CKD stages 1–5 prevalence, including 95% CI.
This prevalence varied between 6.3% (95% CI, 6.0 to 6.5) in
Norway and 25.6% (95% CI, 23.7 to 27.5) in the Northeast
German SHIP study.
The prevalence of CKD stages 1–5 for age categories 20–44
years, 45–64 years, 65–74 years, and 75–84 years is shown in
Supplemental Appendix 1, Figure 2, 1–4, separately for stud-
ies using IDMS and non–IDMS-standardized creatinine as-
says. The CKD stages 1–5 prevalence was lowest in the age
group 20–44 years and increased with every consecutive age
group.
Across Risk Strata
Figure 2, B–D presents the CKD stages 1–5 prevalence in
the population aged 45–74 years of studies using IDMS-
standardized creatinine, stratiﬁed by diabetic, hypertension,
and obesity status. The variation in CKD stages 1–5 prevalence
stratiﬁed by risk factors followed the pattern of the overall
adjusted prevalence across regions. Supplemental Appendix 1,
Figure 1, B–D, show this same pattern in the adult population,
separately for studies using IDMS- and non–IDMS-standardized
creatinine.
CKD Stage 3–5 Prevalence
Adult Population
Supplemental Appendix 1, Figure 3 shows the CKD stages 3–5
prevalence including 95% CI for the adult population, sepa-
rately for IDMS and non-IDMS studies. This CKD stages 3–5
prevalence varied between 1.0% (95% CI, 0.7 to 1.3) in the
Italian Malattie cardiovascolari ATerosclerotiche Istituto Su-
periore di Sanita study and 5.9% (95% CI, 5.2 to 6.6) in the
Northeast German SHIP study.
Supplemental Appendix 1, Table 2 shows the unadjusted
and adjusted CKD stages 3–5 prevalence in the adult popula-
tion, for both IDMS and non-IDMS studies. For studies us-
ing non–IDMS-standardized creatinine, the unadjusted and
adjusted CKD stages 3–5 prevalence in the adult population
Figure 1. Adjusted CKD stages 1–5 prevalence in the population
aged 45–74 years, in IDMS studies. Prevalence was age- and sex-
adjusted to the EU27 population of 2005. The study names in
uncolored regions are studies which used non–IDMS-standardized
creatinine or studies which recruited subjects aged $50 years: the
CKD prevalence results of these studies are shown in Supple-
mental Appendix 1. 3C, Three City Study; ActiFE, Activity and
Function in the Elderly in Ulm study; EPIRCE, Estudio Epi-
demiológico de la Insuﬁciencia Renal en España; HUNT, Nord-
Trøndelag Health Study; INCIPE, Initiative on Nephropathy, of
relevance to public health, which is Chronic, possibly in its Initial
stages, and carries a Potential risk of major clinical Endpoints;
LifeLines, LifeLines Cohort and Study Biobank; MRC, Medical
Research Council trial of assessment and management of older
people in the community; PolSenior, Medical, psychological, so-
ciological and economical aspects of aging of people in Poland;
PREVEND, Prevention of Renal and Vascular End-stage Disease;
SLAN, Survey of Lifestyle and Attitudes & Nutrition in Ireland.
J Am Soc Nephrol 27: 2135–2147, 2016 CKD Prevalence in Europe 2139
www.jasn.org CLINICAL EPIDEMIOLOGY
is graphically presented in Supplemental Appendix 1,
Figure 3A.
Across Age Strata
Figure 3 shows the geographic variation of the adjusted CKD
stages 3–5 prevalence in the population aged 45–74 years, for
studies using IDMS-standardized creatinine. Figure 4A shows
the overall adjusted CKD stages 3–5 prevalence in these stud-
ies, including 95% CI. This CKD prevalence varied between
1.7% (95% CI, 1.3 to 2.1) in the Swiss Bus Santé study and
11.5% (95% CI, 10.2 to 12.8) in the Northeast German SHIP
study.
The prevalence of CKD stages 3–5 for age categories 20–44
years, 45–64 years, 65–74 years, and 75–84 years is shown in
Supplemental Appendix 1, Figure 4, 1–4, separately for
studies using IDMS and non–IDMS-standardized creatinine
assays. The CKD stages 3–5 prevalence was lowest in the
youngest age group and increased with every consecutive
age group.
Across Risk Strata
Figure 4, B–D presents the CKD stages 3–5 prevalence in
the population aged 45–74 years of studies using IDMS-
standardized creatinine, stratiﬁed by diabetic, hypertension,
and obesity status. The variation in CKD stages 3–5 prevalence
stratiﬁed by risk factor followed the pattern of the overall ad-
justed prevalence across regions. Supplemental Appendix 1,
Figure 3, B–D, show this same pattern in the adult population,
separately for studies using IDMS- and non–IDMS-standardized
creatinine.
Figure 2. (A) Adjusted CKD prevalence stages 1–5 (95% CI) in the population aged 45–74 years, in IDMS studies. (B) CKD prevalence
stages 1–5 (95% CI) in the population aged 45–74 years, in IDMS studies, by diabetic status. (C) CKD prevalence stages 1–5 (95% CI) in
the population aged 45–74 years, in IDMS studies, by hypertensive status. (D) CKD prevalence stages 1–5 (95% CI) in the population
aged 45–74 years, in IDMS studies, by obesity status. Prevalence was age- and sex-adjusted to the EU27 population of 2005. N, the
number of study subjects aged 45–74 years with creatinine and albuminuria measurement. Studies not covering the entire age range
are not included in this ﬁgure. DM, diabetes mellitus; EPIRCE, Estudio Epidemiológico de la Insuﬁciencia Renal en España; HUNT,
Nord-Trøndelag Health Study; HT, hypertension; INCIPE, Initiative on Nephropathy, of relevance to public health, which is Chronic,
possibly in its Initial stages, and carries a Potential risk of major clinical Endpoints; LifeLines, LifeLines Cohort and Study Biobank; SLAN,
Survey of Lifestyle and Attitudes & Nutrition in Ireland; Ɵ, studies using enzymatic method; | studies using Jaffe method.
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DISCUSSION
Our study suggests a substantial variation in CKD prevalence
across Europe. Stratiﬁcation by risk factors further suggests
that this variation in CKD prevalence is remarkably consistent
across high- and low-risk populations, implying that the
difference in overall prevalence of CKD is at least in part due
to other factors than the prevalence of diabetes, hypertension,
and obesity in the general population.
Global Perspective
Regional differences in CKD prevalence have been documen-
ted around the world, even when comparing age- and sex-
adjusted prevalence estimates using standardized creatinine
methods. For example, in the adult general population of the
United States, the adjusted CKD stages 3–5 prevalence varied
from 4.8% in the Northeast to 11.8% in the Midwest.13 In
contrast, in China the adjusted CKD stages 3–5 prevalence
showed lower prevalence estimates, from 1.1% in East China
to 3.8% in Southwest China.14 This variation is similar to that
in Europe, where the adjusted CKD stages 3–5 prevalence var-
ied from 1.0% to 5.9%. The adjusted CKD stages 1–5 preva-
lence in China showed larger variation, from 6.7% in South
China to 18.3% in Southwest China.10 In Europe, this adjusted
CKD stages 1–5 prevalence varied from 3.3% to 17.3%.
Explanatory Factors in Europe
There are many factors which potentially contribute to
the observed differences in CKD prevalence across countries
and regions.Weargue that thesedifferencesarepossiblyduetotrue
differences in the prevalence of CKD as well as to heterogeneity of
studies. In the following wewill discuss ﬁve possible explanations.
Human and Environmental Factors
Dietary habits across European regions vary substantially.15
Dietary protein intake is known to inﬂuence serum creatinine
and thus eGFR.16,17 This may not only be an artifact, but also a
true effect, because studies have shown that protein-rich diets
are associated with accelerated eGFR decline.18 Also, the Med-
iterranean diet has been suggested to reduce the risk of devel-
opment of CKD.19 Therefore, regional differences in dietary
habits could lead to a difference in observed CKD prevalence
through both a direct effect on serum creatinine and through
reno-damaging or reno-protective inﬂuences. Additionally,
there are multiple other factors associated with CKD preva-
lence, such as smoking, physical activity,20 socioeconomic
status,21 and birth weight.22 These factors may vary between
regions and may therefore contribute to the observed CKD
prevalence variation.
Public Health Policies
European regions differ greatly with regard to healthcare
policies.23 Public health initiatives may both prevent diseases
and their complications by primary and secondary prevention,
respectively.24 National and regional public health initiatives
may therefore contribute to differences in the prevalence of
underlying causes of CKD, like diabetes, hypertension, and
obesity, as well as to the prevalence of CKD itself.
The consistently higher prevalence of CKD in high-
compared with low-risk groups implies that the focus of public
health initiatives should, indeed, lie with prevention of CKD in
patients with underlying diseases. However, the remarkable
consistency of international variation in CKD prevalence,
irrespective of the presence of risk factors, emphasizes that
the focus of public health initiatives should also liewith primary
Figure 3. Adjusted CKD stages 3–5 prevalence in the population
aged 45–74 years, in IDMS studies. Prevalence was age- and
sex-adjusted to the EU27 population of 2005. The study names in
uncolored regions are studies which used non–IDMS-standardized
creatinine or studies which recruited subjects aged $50 years; the
CKD prevalence results of these studies are shown in Supplemental
Appendix 1. 3C, Three City Study; ActiFE, Activity and Function in
the Elderly in Ulm study; EPIRCE, Estudio Epidemiológico de la
Insuﬁciencia Renal en España; ESTHER, Epidemiologische Studie
zu Chancen der Verhütung, Früherkennung und optimierten THerapie
chronische ERkrankungen in der älteren Bevolkerung; FINRISK,
Finland Cardiovascular Risk Study; HUNT, Nord-Trøndelag Health
Study; INCIPE, Initiative on Nephropathy, of relevance to public
health, which is Chronic, possibly in its Initial stages, and carries a
Potential risk of major clinical Endpoints; LifeLines, LifeLines Cohort
and Study Biobank; MATISS, Malattie cardiovascolari ATerosclerotiche
Istituto Superiore di Sanita; MONA LISA, MOnitoring NAtionaL du
rISque Arterie; MRC, Medical Research Council trial of assessment and
management of older people in the community; PIVUS, Prospective
Investigation of the Vasculature in Uppsala Seniors Study; PolSenior,
Medical, psychological, sociological and economical aspects of aging
of people in Poland; PREVADIAB, Prevalence of Diabetes and Risk
Factors in Portugal; PREVEND, Prevention of Renal and Vascular
End-stage Disease; SLAN, Survey of Lifestyle and Attitudes &
Nutrition in Ireland; VIP, Valle dell’Irno Prevenzione
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preventionofCKD, through the promotion of a healthy lifestyle
in the entire population.
Genetic Factors
In studies which collected ethnicity data, almost all partici-
pants were white. However, even within the white European
populations there are substantial genetic differences.25 Studies
have shown that the development of CKD and the incidence
of RRT are associated with multiple genetic loci.26,27 The
regional differences in CKD prevalence could therefore be
inﬂuenced by genetic differences across the various regions.
This has been shown for the geographic pattern in the
Figure 4. (A) Adjusted CKD prevalence stages 3–5 (95% CI) in the population aged 45–74 years, in IDMS studies. (B) CKD prevalence
stages 3–5 (95% CI) in the population aged 45–74 years, in IDMS studies, by diabetic status. (C) CKD prevalence stages 3–5 (95% CI) in
the population aged 45–74 years, in IDMS studies, by hypertensive status. (D) CKD prevalence stages 3–5 (95% CI) in the population
aged 45–74 years, in IDMS studies, by obesity status. Prevalence was age- and sex-adjusted to the EU27 population of 2005. N, the
number of study subjects aged 45–74 years with creatinine measurement. Studies not covering the entire age range are not included in
this ﬁgure. DM, diabetes mellitus; EPIRCE, Estudio Epidemiológico de la Insuﬁciencia Renal en España; FINRISK, Finland Cardio-
vascular Risk Study; HUNT, Nord-Trøndelag Health Study; INCIPE, Initiative on Nephropathy, of relevance to public health, which is
Chronic, possibly in its Initial stages, and carries a Potential risk of major clinical Endpoints; LifeLines, LifeLines Cohort and Study
Biobank; MATISS, Malattie cardiovascolari ATerosclerotiche Istituto Superiore di Sanita. Ɵ studies using enzymatic method; | studies
using Jaffe method.
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prevalence of RRT for IgA nephropathy.28 Because 7.1% of
all RRT is provided for hereditary nephropathies (European
Renal Association–European Dialysis and Transplant Associ-
ation Registry, unpublished data), it is to be expected that
some of the variation in CKD prevalence is also due to genetic
differences.
Heterogeneity in Laboratory Methods
In addition to reﬂecting true differences inCKDprevalence, our
results may also vary due to the heterogeneity of methodology
used to measure creatinine5 and albuminuria,29 including dif-
ferences in assays but also in handling and storage conditions
(e.g., duration as well as number of freeze and thaw cycles until
analysis).29,30
Differences in creatinine assays will likely contribute to the
variation in CKD prevalence, as most Jaffe assays overestimate
serum creatinine.5 The resulting bias may vary depending on
the creatinine concentration, speciﬁc assay, manufacturer, and
calibration material used.31,32 Fortunately, the IDMS calibra-
tion standardization has reduced the bias and improved the
interlaboratory comparability.5,32 Despite the use of IDMS
standardization, some interlaboratory variability still ex-
ists,31 being lowest in IDMS-standardized enzymatic assays.5
Notably, our study shows substantial differences in CKD
stages 3–5 prevalence across studies using enzymatic IDMS-
standardized assays. In these studies, the adjusted CKD stages
3–5 prevalence in the age group 65–74 years varied from 4.8%
in central Italy to 11.4% in Finland.
Moreover, CKD stages 1–5 prevalence may additionally be
inﬂuenced by albuminuria assays.29 As recommended byKidney
Disease Improving Global Outcomes (KDIGO), urinary albu-
min was measured by immunoassays in 91% of studies and we
used urinary albumin-to-creatinine ratio for the deﬁnition of
CKD.1 Importantly, there is no standardization available to en-
hance comparability of immunoassays across laboratories.29
Heterogeneity in Study Populations
Finally, differences in prevalence may have resulted from
differences in population sample selections. As in the United
States, CKD prevalence in Europemay have changed over time,
and this might explain some of the observed differences.33
Nevertheless, we found both high and low CKD preva-
lence in older and in more recent studies. For example,
in studies performed in the period 2005–2010 using the
IDMS-standardized Jaffe method, the adjusted CKD stages 3–
5 prevalence in the age group 65–74 years ranged from 4.1%
in Switzerland to 20.8% in South Germany. This suggests that
differences in time periods cannot fully explain the observed
differences in CKD prevalence.
Although all studies were designed to be representative of
the respective regional or national general population, their
sample selections varied substantially as outlined in Table 1.
Sample selection methods inﬂuence the coverage of the pop-
ulation investigated and inﬂuence the response, which both
inﬂuence the ultimate representativeness of the sample.34,35
We have checked the representativeness of the included studies
by comparing the age and sex distribution of the study pop-
ulations to the relevant census data. Although overall the study
populations appear to be representative for the age and sex
distribution of their target population, we cannot exclude a
selection bias based on unmeasured factors, such as the pres-
ence of (unmeasured) comorbidities.
Studies with high response are less likely to suffer from
nonresponse bias, yet the impact of nonresponse bias on
representativeness is not solely determined by the response.34
Even with low response a sample may be highly representative
by chance alone. To date, there is no validated method to mea-
sure the inﬂuence of nonresponse bias on the representative-
ness of study results.34,36 However, nonresponse analyses can
provide some insight into the likely direction of a possible non-
response bias.34 All nonresponse analyses performed by the
individual studies suggested that recruited participants were
similar or healthier in comparison to nonparticipants.7–11
This might have led to an underestimation of the true CKD
prevalence in these studies.
Strengths and Limitations
The new European CKDBurden Consortium enabled this ﬁrst
large-scale study to describe CKD prevalence across Europe.
The comparability of CKD prevalence across studies was
increased by using the same deﬁnition based on one eGFR
equation.Additionally, we only compared studies using IDMS-
standardized creatinine to increase interlaboratory compara-
bility of creatinine results. Moreover, the comparability of
study populations across European countries was enhanced by
removing the inﬂuence of differences in national age and sex
distributions through age and sex standardization to the EU27
population.12 Finally, to avoid the inﬂuence of international
differences in the prevalence of diabetes, hypertension, and
obesity, we determined CKD prevalence in subgroups with
and without these risk factors.
There are also limitations to this study. First, the prevalence
of CKD might have been slightly overestimated using single
creatinine and albuminuria measurements. However, this will
not have inﬂuenced the variation of CKD prevalence across
studies, as all estimations will be equally affected. Ethnicity
status was not included in the eGFR equation because this was
not available for all studies, which might have led to a slight
overestimation of CKD prevalence in some studies. However,
in studies which did collect ethnicity data, at least 96% were
white; therefore, the expected impact on the overall prevalence
estimation is negligible. Other limitations relate to the hetero-
geneity of included studies with regard to laboratory methods
and sample selection. This heterogeneitymight have inﬂuenced
the variation of CKD prevalence as discussed. The ﬁrst may be
solved by central measurement of serum creatinine and albu-
minuria in a reference laboratory. The effect of response, how-
ever, is inherent to population surveys and cannot be avoided.
In conclusion, this is the ﬁrst study which carefully charac-
terizes CKD prevalence across Europe. Our results suggest
J Am Soc Nephrol 27: 2135–2147, 2016 CKD Prevalence in Europe 2143
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substantial variation in CKD prevalence across population
samples in Europe. These differences are possibly due to true
differences in the prevalence of CKD as well as to heterogeneity
of the laboratory and sample selection methods. The effect of
the variation in European regions with regard to human and
environmental factors, public health policies, and genetics on
CKD prevalence needs further investigation.
Our results may be used to guide future projections of the
CKD burden in Europe and thereby help estimate the growing
demand for CKD services that the ageing populationwill likely
create. Our results are also a ﬁrst step inmonitoring the impact
of strategies designed to reduce the burden of CKD in Europe.
Thismonitoringmay assist themedical community and policy




We ﬁrst systematically searched scientiﬁc publications, to identify
European studies with data on CKD prevalence in the general
population (details described in Supplemental Appendix 2).37 Addi-
tionally, the representatives of national kidney foundations, renal
registries, and expert nephrologists in 39 European countries were
asked to provide contact details for any relevant unpublished stud-
ies. Studies were included if they were designed to select a represen-
tative sample of the adult general population and CKD prevalence
could be calculated. Studies that ended recruitment prior to 1996
were excluded. Eligible studies were invited to participate in an on-
line questionnaire, assessing general study information (e.g., period
of participant inclusion), collected data, and regional healthcare
system characteristics. Answers regarding collected data and health-
care system characteristics are shown in Supplemental Appendix 2,
Tables 1 and 2, respectively. Finally, studies that agreed to contribute
data were sent a statistical analysis syntax to collect aggregated data.
All studies were approved by local ethical committees and all par-
ticipants gave consent.
All studies which contributed data were included in the Euro-
pean CKD Burden Consortium. The European CKD Burden Consor-
tium, including nephrologists and epidemiologists, was established
to characterize CKD prevalence and progression of CKD across
Europe.
Collected Data
Data were collected for the total study population and for subgroups
by age (#.65 years), sex, and by diabetes, hypertension, and obesity
(body mass index $30 kg/m2) status. For the continuous variables
age, systolic and diastolic blood pressure, body mass index, eGFR,
and urinary albumin-to-creatinine ratio, we collected the mean
(SD) and median (25th and 75th percentiles). In addition, we col-
lected the following factors known to inﬂuence kidney function: the
proportion of current smokers and individuals using angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers.
Furthermore,we collected the laboratorymethods for themeasurement
of serum creatinine and detection of albuminuria. Serum
creatinine was measured by a Jaffe or enzymatic method, both of
which can be standardized to IDMS.32 Diabetes was deﬁned as
self-reported diabetes and/or the use of glucose lowering medica-
tion. Hypertension was deﬁned as a systolic blood pressure of
$140 mmHg, a diastolic blood pressure of $90 mmHg, or the use
of antihypertensive drugs.
Deﬁnition of CKD
1. CKD stages 1–5: eGFR,60 ml/min per 1.73 m2 calculated
by the CKD-Epidemiology Collaboration equation1,38 and/or
uACR$30 mg/g.
2. CKD stages 3–5: eGFR,60 ml/min per 1.73 m2 calculated by the
CKD-Epidemiology Collaboration equation.
These deﬁnitions were based on the KDIGO practice guideline.1 As
no studies repeated measurements after three months, the chronicity
criterion (symptoms $3 months) was not applied to the deﬁnition.
Statistical Analyses
Normally distributed variables are presented as means with SD, and
non-normally distributed data as medians with interquartile ranges.
Dichotomous data are given in percentages. The representativeness of
study populations was tested by comparing the age and sex distri-
bution of the study population to the distribution of the relevant
regional/national population using the chi-squared test. The preva-
lence of CKD stages 1–5 andCKD stages 3–5with 95%CI is presented
as unadjusted rates and weighted averages using the age and sex dis-
tribution of the 2005 EU27 population.12 To limit the inﬂuence of
random variation, this adjustment was only applied to studies with a
minimum of 100 participants per included age stratum. Conse-
quently, (sub)groups with insufﬁcient numbers were excluded from
this adjustment. Additionally, we stratiﬁed study populations into the
following age groups: 45–74, 20–44, 45–64, 65–74, and 75–84 years,
and whenever possible adjusted for the effect of age within strata. The
age-stratiﬁed CKD prevalence is given for the overall study popula-
tion as well as by diabetic, hypertension, and obesity status.
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